Discussing the Efficacy of Alemtuzumab

Alasdair Coles, MD, University of Cambridge, shares his thoughts on the efficacy of alemtuzumab for patients with multiple sclerosis (MS) at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.

Results from a 4-year study showed that patients who had been given alemtuzumab displayed much less severe disability and low relapse rate than those recorded at baseline.